To evaluate the role of intravitreal Triamcinolone (TA) in the early management of Coats’ disease with or without trans-scleral drainage.


Retrospective, interventional case series. Fifteen consecutive cases with Coats’ disease were managed with 4mg/0.1ml intravitreal Triamcinolone injection on presentation and were followed up for a minimum duration of one year. Additional management strategies included drainage of subretinal fluid through an inferior sclerotomy, peripheral laser ablation and/or cryotherapy, cataract extraction, and vitrectomy.

Effectiveness / Safety:

Improvement of visual acuity was achieved compared to preoperative vision in all cases even when 40% of eyes required cataract extraction and intraocular lens implantation surgery. One patient needed anti glaucoma treatment to control raised intraocular pressure.

Take home message:

Intravitreal TA has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats disease. However, TA treatment is this age group is associated with the development of cataract in 40 % cases.